Knocking out part of the innate immune system to improve cancer therapy
Researchers at Shanghai Jiao Tong University School of Medicine, China, have discovered that shutting down part of the innate immune system increases anti-tumor activity.
Researchers at Shanghai Jiao Tong University School of Medicine, China, have discovered that shutting down part of the innate immune system increases anti-tumor activity.
Influenza A viruses spawn epidemics, global pandemics and sweeping outbreaks that kill millions of birds, yet only now have flu scientists obtained comprehensive, high-resolution structural data on a protein that is key to ...
A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine. The findings ...
Jun 28, 2017
1
50
(Medical Xpress)—Commensal microbiota, populations of bacteria that inhabit the tissues of larger organisms, often have complex relationships with their hosts. Researchers have been aware for some time that commensal microbiota ...
(Medical Xpress)—To move material in bulk, the standard shipping container used by cells, is the vesicle. These approximately 40-micron sized spheres are essentially recyclable grocery bags that can be loaded and adorned ...
(Medical Xpress)—Nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed, researchers at Washington University School of Medicine in St. ...
Mar 8, 2013
3
0
A combination of two antiviral compounds may be a promising alternative to Paxlovid when treating COVID-19 in immunocompromised patients, according to Karen S. Anderson, Ph.D., professor of pharmacology and of molecular biophysics ...
Apr 30, 2024
0
121
A collaboration between the University of Tasmania and Royal Hobart Hospital Pathology has revealed the consequences of using molnupiravir to treat COVID-19.
Apr 8, 2024
0
45
The COVID-19 virus can persist in the blood and tissue of patients for more than a year after the acute phase of the illness has ended, according to new research from UC San Francisco that offers potential clues to why some ...
Mar 7, 2024
0
597
The currently recommended five-day course of molnupiravir, an antiviral treatment, may not be long enough to treat COVID-19, according to a new paper involving UCL researchers.
Feb 27, 2024
0
28